drug_type
RELEVANT_DRUG
intervention_type
Genetically modified autologous T-cell (TCR T-cell) therapy
drug_description
Autologous genetically modified TCR-engineered SPEAR T-cell therapy expressing an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-expressing CD8αβ to enhance class I–restricted cytotoxicity; designed to recognize HLA-A2/MAGE-A4 on tumor cells and kill them.
nci_thesaurus_concept_id
C162804
nci_thesaurus_preferred_term
Uzatresgene Autoleucel
nci_thesaurus_definition
Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, uzatresgene autoleucel bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express an affinity-enhanced TCR specific for the MAGE-A4 peptide presented by HLA-A2 and co-express CD8alpha/beta; following infusion they recognize HLA-A2/MAGE-A4 on tumor cells and mediate class I-restricted cytotoxic killing.
drug_name
ADP-A2M4CD8
nct_id_drug_ref
NCT05601752